JPRN-jRCT2080220192未知2 期
A multi-center, open label, non-randomized, phase II study to assess the activity and safety of cetuximab plus irinotecan in subjects with EGFR-detectable metastatic colorectal carcinoma
Bristol-Myers K.K.0 个研究点目标入组 38 人开始时间: 2005年12月21日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 38
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 74age old（—）
- 性别
- All
入选标准
- •1. Diagnosis of histologically confirmed, metastatic colorectal carcinoma (CRC) that is surgically unresectable. 2. Immuno histochemical evidence of EGFR expression. 3. Patients who have documented progressive disease to irinotecan based chemotherapy. 4. Patients who have failed previous fluoropyrimidine based chemotherapies. 5. Patients who have failed previous oxaliplatin-based chemotherapies. 6. Presence of at least one unidimensionally measurable lesion (target lesion by RECIST criteria). 7. Performance Status : 0 - 2
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.EUCTR2013-003579-36-ITBayer HealthCare AG50
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.Pediatric patients with solid malignant tumors that are recurrent or refractory to standard therapy.EUCTR2013-003579-36-FRBayer HealthCare AG50
进行中（未招募）
1 期
Safety, tolerability and pharmacokinetics of regorafenib in pediatric subjects.RMS and other solid malignant tumors (Ewing sarcoma, hepatoblastoma, neuroblastoma and Wilms tumor) in which treatment with vincristine/irinotecan is considered backbone chemotherapy at relapse and a scientific rationale to combine irinotecan with regorafenib exists.MedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864EUCTR2013-003579-36-GBBayer AG77
进行中（未招募）
不适用
An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) in patients with follicular non Hodgkin’s lymphoma with no prior treatment - FL2008 RGMEUCTR2007-005580-95-FRGoelams
进行中（未招募）
不适用
An open label, multicenter, non randomized phase II study to evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with RCHOP chemotherapy and Rituximab (MabThera®) maintenance in patients with first-line advanced follicular non Hodgkin’s lymphoma - FL2008 RCHOPGMThis study evaluate anti-tumor efficacy and safety of GM-CSF (sargramostim, Leukine®) associated with Rituximab (MabThera®) and chemotherapy (CHOP) in patients with non bulky follicular non Hodgkin’s lymphoma with no prior treatment.MedDRA version: 9.1Level: LLTClassification code 10025310Term: LymphomaEUCTR2007-007056-33-FRGoelams